GlassScriptPhysician profile
Syeda Nida
NPI 1629690763
$895.00
in general payments reported to CMS, 2019-2025
13 companies · $388 in 2025
The $388 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $51.74 · 2024: $455 · 2025: $388.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $895.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $895.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $240.24 | 2024-2025 | Tavneos, Otezla, Evenity |
| Aurinia Pharma U.S., INC. | $159.36 | 2023-2025 | Lupkynis |
| Ucb, INC. | $88.58 | 2024-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $70.81 | 2024-2025 | Tremfya |
| Sobi, INC | $69.09 | 2024-2025 | |
| Kyowa Kirin, INC. | $62.55 | 2024-2025 | Crysvita |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.85 | 2024-2025 | Cyltezo |
| Novartis Pharmaceuticals Corporation | $41.52 | 2024-2025 | |
| Janssen Scientific Affairs, LLC | $36.39 | 2025 | Tremfya |
| Abbvie INC. | $28.07 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $19.13 | 2025 | Orencia |
| Kiniksa Pharmaceuticals, LTD. | $17.16 | 2023 | Arcalyst |
| Astrazeneca Pharmaceuticals LP | $16.25 | 2025 | Saphnelo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Syeda Nida listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.